Clinical Trial Update: PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating PR1-specific cytotoxic T-lymphocyte infusion for recurrent chronic myelogenous leukemia after allogeneic hematopoietic transplantatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• PR1-Specific Cytotoxic T-Lymphocyte Infusion (PR1-specific cytotoxic T lymphocytes)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelogenous Leukemia | Phase 1 | Status: WITHDRAWN